ACUTE MYOCARDIAL INFARCTION

โœ“ Medically ReviewedCARDIOVASCULARID: MDBTH004ICD-11: BA41๐Ÿšจ CRITICAL PROTOCOL
๐Ÿ’ก Core Clinical Guidance

Acute myocardial infarction (AMI) is the irreversible necrosis of myocardial tissue resulting from sustained ischaemia caused by abrupt reduction or total occlusion of coronary artery blood flow. It is characterised by a rise and/or fall in cardiac biomarkers (troponin) with at least one value above the 99th percentile upper reference limit, in the context of symptoms or ECG changes consistent with acute myocardial ischaemia.

๐Ÿ“–

Definition

CLINICAL DEFINITION & PATHOPHYSIOLOGY

Acute myocardial infarction (AMI) is the irreversible necrosis of myocardial tissue resulting from sustained ischaemia caused by abrupt reduction or total occlusion of coronary artery blood flow. It is characterised by a rise and/or fall in cardiac biomarkers (troponin) with at least one value above the 99th percentile upper reference limit, in the context of symptoms or ECG changes consistent with acute myocardial ischaemia.

๐Ÿ’Š

Pharmacological Management โ˜…

FIRST-LINE REGIMENS
300 mg loading, then 75 mgPOOnce dailyLifelong

Antiplatelet: immediate loading dose at presentation

๐Ÿ’Š Ticagrelor

PREFERRED
180 mg loading, then 90 mgPOTwice daily12 months (DAPT)

Preferred P2Y12 inhibitor in ACS; superior to clopidogrel (PLATO trial)

ALTERNATIVE & ESCALATION REGIMENS

๐Ÿ’Š Clopidogrel

300โ€“600 mg loading, then 75 mgPOOnce daily12 months

Alternative if ticagrelor/prasugrel contraindicated or unavailable

ADJUNCTIVE & ADD-ON THERAPIES

๐Ÿ’Š High-intensity statin (Atorvastatin 40โ€“80 mg daily) โ€” initiated immediately, continued lifelong

๐Ÿ’Š Beta-blocker (Bisoprolol 2.5โ€“10 mg) โ€” if no contraindication; reduces reinfarction and mortality

๐Ÿ’Š ACE inhibitor (Ramipril 2.5โ€“10 mg) โ€” initiated within 24 hours if LVEF reduced; all with anterior MI or LV dysfunction

๐Ÿ’Š Aldosterone antagonist (Eplerenone) โ€” if LVEF โ‰ค40% or clinical heart failure, already on ACEi and beta-blocker

๐Ÿ’Š Unfractionated heparin or LMWH (anticoagulation during acute phase)

๐Ÿ’Š Glyceryl trinitrate (GTN) for ongoing chest pain (avoid if RV infarction or hypotension)

๐Ÿ’Š STEMI: primary PCI within 90 minutes of first medical contact ('door-to-balloon' time)

๐Ÿ’Š If PCI unavailable within 120 minutes: thrombolysis with Tenecteplase

SPECIAL PATIENT POPULATIONS
PREGNANCY
  • Heparin preferred over warfarin
  • Aspirin and ticagrelor used under specialist guidance
  • Primary PCI preferred over thrombolysis
GERIATRICS
  • Higher bleeding risk with dual antiplatelet therapy
  • Consider half-dose thrombolysis if primary PCI unavailable
  • Risk-benefit assessment for aggressive intervention in frail elderly
PAEDIATRICS
  • Rare; consider congenital anomalies, Kawasaki disease
  • Specialist cardiology management
RENAL IMPAIRMENT
  • Adjust dose of renally cleared agents
  • Contrast nephropathy risk during PCI: IV hydration, minimise contrast volume
  • Bivalirudin may be preferred over heparin in severe CKD
HEPATIC IMPAIRMENT
  • Avoid statins in severe hepatic failure
  • Ticagrelor: avoid in severe hepatic impairment
CONTRAINDICATIONS & SAFETY CAUTIONS
  • Ticagrelor: avoid if previous intracranial haemorrhage, active bleeding, hepatic failure
  • Prasugrel: avoid in prior stroke/TIA, age >75 years, weight <60 kg
  • Beta-blockers: avoid in cardiogenic shock, severe asthma, second/third degree AV block
  • ACE inhibitors: avoid in bilateral renal artery stenosis, pregnancy, hyperkalaemia
  • Thrombolysis: contraindicated in aortic dissection, recent surgery, active bleeding, haemorrhagic stroke
โš–๏ธCLINICAL NOTICE & EDUCATIONAL DISCLAIMER

All content in Medobo is for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional and local institutional protocols before administering medication or initiating treatment.